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Adherence  measurement  for  microbicide  use  within  the  clinical  trial  setting  remains  a  challenge  for  the
HIV  prevention  ﬁeld.  This  paper  describes  an  assay  method  used  for  determining  residual  dapivirine  lev-
els in  post-use  vaginal  rings  from  clinical  trials  conducted  with  the  Dapivirine  Vaginal  Matrix  Ring-004
developed  by  the International  Partnership  for Microbicides  to prevent  male  to female  HIV  transmission.
Post-use  assay  results  from  three  Ring-004  clinical  trials  showed  that  of  the  25 mg  drug load,  approxi-
mately  4 mg of dapivirine  is released  from  the  matrix  ring  over  a 28-day  use  period.  Data  obtained  by
both  in vitro and  in  vivo  studies  indicate  that  dapivirine  is  released  according  to a diffusion  mechanism,
as  determined  by conformance  of both  data  sets  to the  Higuchi  equation.  This,  coupled  with  the  low
variability  associated  with  batch  production  over  two  manufacturing  sites  and  20 batches  of material,
provides  evidence  that post-use  ring  analysis  can  contribute  to  the  assessment  of adherence  to  ring use.n vitro drug release
dherence model
Limitations  of  this  method  include  the  potential  of  intra-participant  and  inter-participant  variability  and
uncertainty  associated  with  measuring  the  low  amount  of  dapivirine  actually  released  relative  to the
drug  load.  Therefore,  residual  drug  levels should  not  serve  as  the  only  direct  measurement  for  micro-
bicide  adherence  in  vaginal  ring  clinical  trials  but  should  preferably  be  used  as  part of a  multi-pronged
approach  towards  understanding  and  assessing  adherence  to vaginal  ring  use.
©  2016  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Introduction
Topical vaginal microbicides represent a promising prevention
echnology with the potential to fulﬁl the need for woman-initiated
IV prevention options. Numerous clinical trials have been con-
ucted over the past 15 years, with vaginal microbicide products
ontaining a range of active pharmaceutical ingredients (APIs),
rimarily in gel formulation for coitally-associated use. Only one
roduct, a gel formulation of the antiretroviral tenofovir, has
emonstrated efﬁcacy in a clinical trial, but results from a subse-
uent tenofovir trial failed to conﬁrm efﬁcacy [1,2a]. Increasingly,
he inability to demonstrate efﬁcacy of candidate microbicides is
ttributed, at least in part, to poor user-adherence in large scale
linical trials [2], underlying the importance and need for the devel-
pment and optimization of robust adherence measures in anti-HIV
icrobicide trials.
∗ Corresponding author.
E-mail address: pspence@ipmglobal.org (P. Spence).
ttp://dx.doi.org/10.1016/j.jpba.2016.03.023
731-7085/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
Adherence assessment for vaginal microbicides has proven chal-
lenging. As Karim et al. observe, “Adherence levels are dependent
on human behavior in the context of the user’s social environment,
whereas the available concentration of the drug is affected by its
pharmacological properties and host-cell biology.” [3]. Similar to
many other health care products, trial participants may  over-report
microbicide use because of a social desirability bias, due to the pos-
sibility that they may  not fully understand the questions about their
product use, and/or they may  not accurately recall use [4].
Self-administered vaginal rings (VRs) are a promising method
for delivery of topical antiretroviral microbicides and potentially
offer an adherence advantage for women over daily or coitally-
dependent dosage forms such as gels. VR dosage forms release
the active substance over an extended period of time, often weeks
or even months. A vaginal ring developed by the International
Partnership for Microbicides (IPM), containing the antiretroviral
dapivirine, a non-nucleoside reverse transcriptase inhibitor, is cur-
rently in Phase III clinical development. Two  pivotal Phase III safety
and efﬁcacy trials with this dapivirine vaginal ring (Ring-004) are
ongoing with results expected in 2015–2016 [5].
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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VR design generally falls into two major categories [6]: Reservoir
ings, which contain an inner “core” of API(s) dispersed or dissolved
n a solution, and an outer layer of pure polymer; and Matrix rings
hat are uniform dispersions of API(s) within a polymer matrix. The
ost common polymers used in both ring types are silicone, ethinyl
inyl acetate, or polyurethane. The IPM vaginal Ring-004 currently
n Phase III development is a platinum-catalyzed silicone ring, con-
aining 25 mg  of dapivirine in a matrix formulation, designed to
chieve release of dapivirine over a 28-day period [7a–c].
Initial clinical trials of the dapivirine VR [7b–d] included analysis
f plasma and vaginal ﬂuid drug levels. This body of bioanalytical
ork indicated release of dapivirine from the ring at safe levels and
resence of signiﬁcant (but variable) levels of dapivirine locally in
he vagina, supporting the continued advancement of the 25 mg
apivirine matrix vaginal ring [7c–d]. Because of the high inter- and
ntra-participant variability of PK results observed in clinical trials
ith the dapivirine VR, even in tightly-controlled Phase I trials, an
lternative, more objective measure is needed to understand the
rue level of adherent use of the VR and drug release (implying
ocal and potentially systemic absorption) for large-scale clinical
rials.
Standard analytical technologies can be used to characterize
Rs. Analytical assessments of VRs have, to this point, primarily
ocused on the critical design aspect of drug release [8]. This paper
escribes the validation (via a simulated use stability study using
imulated vaginal ﬂuid and whole blood) and results obtained from
n assay method used for determining post-use residual dapivirine
evels in VRs used by women in the clinical trial setting. Further-
ore, the utilization of this methodology as a potential tool to
easure clinical trial adherence is discussed.
. Materials and methods
Rings were prepared by dispersion of micronized dapivirine in
ilicone oil. The dispersion was thoroughly mixed in equal amounts
n “Part A” and “Part B” Liquid Silicone Rubber (LSR) kits provided
y Nusil Technologies, Inc. (Carpertina, CA, USA). The LSR kits con-
ain a proprietary blend of components necessary to reliably and
eproducibly form vaginal rings through a platinum-catalyzed pro-
ess. The mixtures of dispersed dapivirine are combined via static
ixer and injected into ring molds. Removal of the inhibitor and
olymerization to form the ring matrix occurs upon heating to ca.
85 ◦C for about one minute.
.1. Preparation of proxy (simulated) vaginal ﬂuid
Proxy (simulated) vaginal ﬂuid was prepared similar to the
ethodology described by Owen and Katz [9]. The simulated
aginal ﬂuid (pH 4.2) was prepared by accurately weighing the
ollowing ingredients into a 500 ml  glass beaker: 1.8 g sodium chlo-
ide (Fluka, Aston Manor, South Africa) 0.7 g potassium hydroxide
Fluka), 0.11 g calcium hydroxide (Merck, Halfway House, South
frica), 0.2 g urea (Merck), 2.5 g glucose (Merck), 9 mg  bovine serum
lbumin (Amresco, Sloane Park, South Africa) and 0.08 g 100% glyc-
rol (SAARCHEM, distributed by Merck). Approximately 400 ml
eionized water and 1 ml  of 90% lactic acid (Merck) were added
o the beaker. The solution was stirred until all of the salts were
issolved. The pH was then adjusted to 4.2 with a mixture (1:1,
/v) of acetic acid (Merck) and water. The solution was transferred
o a 500 ml  volumetric ﬂask and the volume was adjusted to exactly
00 ml  with deionized water. The proxy-vaginal ﬂuid was stored at
◦C for a period of 4 months. Biomedical Analysis 125 (2016) 94–100 95
2.2. Vaginal rings used in simulated use studies and clinical trials
The VRs used for simulated use studies and for clinical trial sup-
ply were manufactured for IPM by QPharma (Malmö, Sweden).
2.3. Simulated use and assay of vaginal rings
2.3.1. Preparation of simulated post-use vaginal rings
Unused VRs (25 mg  dapivirine per ring) were subjected to post-
use storage and transport conditions similar to VRs from ongoing
Phase III clinical trials prior to analysis (e.g., storage in a sealed
plastic bag at either −20 ◦C or room temperature). These VRs were
tested for appearance and assay only. Acceptable stability at room
temperature and −20 ◦C has been demonstrated for 6 months and
24 months, respectively.
2.3.2. Simulated use conditions
Simulated use conditions were performed to support the lack of
impact of biological ﬂuids on the post-use extraction/analysis, and
to probe the effect of not rinsing the rings prior to extended storage
(i.e., for shipment to the bioanalytical laboratory for analysis). The
following conditions were investigated at both room temperature,
up to 6 months, and −20 ◦C, up to 24 months.
2.3.2.1. Whole blood, rinsed. VRs were submerged in fresh (never
frozen) pooled whole blood (anti-coagulant, K3-EDTA), rinsed
under tap water, blotted dry, and sealed into appropriately labelled
plastic bags. Rings were stored at room temperature and −20 ◦C.
2.3.2.2. Whole blood, not rinsed. VRs were subjected to the same
procedure as described above, but the rings were not rinsed. Rings
were stored at room temperature and at −20 ◦C.
2.3.2.3. Proxy (simulated) vaginal ﬂuid, rinsed. VRs were submerged
in proxy-vaginal ﬂuid for, rinsed under tap water, blotted dry and
sealed into appropriately labelled plastic bags. Rings were stored
at room temperature and −20 ◦C.
2.3.2.4. Proxy (simulated) vaginal ﬂuid, not rinsed. VRs were sub-
jected to the same procedure as described above, but the rings were
not rinsed. Rings were stored at room temperature and −20 ◦C.
2.3.2.5. Control rings. VRs were not subjected to any treatment.
They were sealed in appropriately labelled plastic bags. Rings were
stored at room temperature and −20 ◦C.
2.3.3. Sample handling for post-use ring analysis
Prior to receipt in the laboratory, used rings were collected at
the clinical Phase I unit, stored for up to one month at room temper-
ature (if storage for longer than 1 month was required, rings were
transferred to a −20 ◦C freezer), then sent to the laboratory for anal-
ysis. Samples were examined for visible microbial contamination
prior to delivery to the analytical laboratory. Rings that showed
visible signs of microbial contamination were discarded without
testing.
2.3.4. Assay methodology
Analysis was  conducted using acetone extraction, and high-
pressure liquid chromatography (HPLC) similar to the procedure
described by Lyndgaard et al. [10]. Minor modiﬁcations, such
as changing from multi-point to single point calibration were
performed, following appropriate crossover or supplemental vali-
dation studies. The method was validated for linearity and accuracy
over the range of approximately 0.2 mg/ring–25 mg/ring. Selec-
tivity, precision, robustness, and system suitability were also
evaluated and results passed expected acceptance criteria.
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Table 1
Results of simulated use studies: 24-month data.
Description Condition Time Point (months) Assay (% LC, mean)a RSDb (%, n = 3)
Control N/A 0 100.8 0.6
Room Temperature 6 98.6 N/Ac
−20 ◦C 6 99.2 0.4
Room Temperature 12 99.1 0.2
−20 ◦C 12 99.5 0.6
Room Temperature 24 100.8 0.7
−20 ◦C 24 99.5 0.8
SVF,  rinsed N/A 0 100.7 0.1
Room Temperature 3 103.1d 0.2
−20 ◦C 3 101.3 0.4
Room Temperature 6 100.0 0.8
−20 ◦C 6 99.2 0.4
−20 ◦C 12 99.1 0.8
−20 ◦C 24 100.5 0.9
SVF,  not rinsed N/A 0 100.6 0.4
Room Temperature 3 102.0d 0.5
−20 ◦C 3 100.7 0.8
Room Temperature 6 99.3 0.5
−20 ◦C 6 98.3 0.8
−20 ◦C 12 98.7 1.0
−20 ◦C 24 99.3 0.8
Whole  blood, rinsed N/A 0 100.5 0.1
Room Temperature 3 105.0d 0.8
−20 ◦C 3 104.5d 1.9
Room Temperature 6 99.2 0.7
−20 ◦C 6 97.6 1.2
−20 ◦C 12 97.5 0.9
−20 ◦C 24 99.6 1.1
Whole  blood, not rinsed N/A 0 100.9 0.8
Room Temperature 3 102.2d 0.5
−20 ◦C 3 103.9d 1.4
Room Temperature 6 99.5 1.2
−20 ◦C 6 99.6 0.4
−20 ◦C 12 98.5 0.8
−20 ◦C 24 101.6 1.4
a Label Claim (LC) based on 25 mg  theoretical dapivirine amount.
b Relative Standard Deviation.
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ac Not Applicable—mean assay value based on n = 2 due to analytical error.
d Atypical values were obtained at the 3-month time point of the study. Results o
mproper sample handling, and are disregarded for trending purposes.
. Results and discussion
.1. Simulated use testing
The methodology of choice for determination of dapivirine con-
ent in used VRs is similar to the assay method initially used to
elease the clinical drug product following manufacturing. In order
o test the applicability of the methodology, the drug product VR
as subjected to simulated use conditions, i.e., exposure to simu-
ated vaginal ﬂuid or whole blood, followed by extraction, analysis
nd comparison to results from the control VR using identical
ethodology. In order to validate the potential holding times and to
ssess long-term impact of exposure to ﬂuids and rinsing processes,
imulated used rings were stored for 6 months at room tempera-
ure (20–25 ◦C) and 24 months at −20 ◦C. Results from simulated
se studies are presented in Table 1. No visible signs of microbial
rowth were noted in any of the samples stored at either condition.
With the exception of the 3-month time point (where a sample
andling error occurred), data are consistent with the hypothesis
hat rings can be stored either at room temperature or in the freezer
or extended periods prior to analysis with no impact on the assay
alue.Similar to matrix transdermal delivery systems, matrix VRs are
ot designed to release the entire drug loaded into the matrix. Drug
elivery happens through a diffusion-controlled system (Eq. (1)),
nd in vitro drug release models the Higuchi equation.investigation performed indicated that the high values obtained were likely due to
Eq. (1):
Q = [Dm
(
2A − Cp
)
Cpt]
1/2
where Q is the cumulative release per unit area (mg cm−2), Dm is the
apparent diffusion coefﬁcient (cm2 day−1) of the substance through
the polymer matrix, A is the loading per unit volume (mg  cm−3), Cp
is the solubility of the substance in the polymer matrix (mg cm−3),
and t is time (days).
“Batch 1” and “Batch 2” (Fig. 1) represent the extremes of the
rates of release observed in the 25 mg  dapivirine matrix vaginal
rings produced to date, which spans over 20 lots at two different
manufacturing sites. F2 similarity is demonstrated at all time points
tested, as evidenced by the maximum absolute percent difference
of 7.2%, noted at the 28-day time point. In simulated vaginal ﬂuid,
the release of dapivirine also appears to model the Higuchi equa-
tion; although the amount released is signiﬁcantly lower (Fig. 2),
clearly a result of the lower dapivirine solubility in this media. The
amount of dapivirine was  not measurable in the media after 10
days.
From an analytical perspective, the amount of residual
dapivirine in used rings provides an indication of how much
dapivirine was  released over the use period. However, the residual
amount of dapivirine will vary, depending on the conditions and
duration of use, where “use” can be deﬁned as either participant
use per protocol (e.g., vaginal insertion, worn for 28 consecutive
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Fig. 1. Representative in vitro drug release for the dapivirine ring.
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Fig. 2. Release of dapivirine in simulated vaginal ﬂuid (SVF) media as compared to
the  media described in the QC method.
Dissolution conditions: simulated vaginal ﬂuid or 50:50 2-propanol:water, 37 ◦C,ot occur on the weekends). Cumulative release percent is based on 25 mg loading
f  ring.
ays), or any exposure condition for any speciﬁed period of time
e.g., in vitro release testing where the ring is submersed in a solu-
ion for 28 days). The amount of dapivirine remaining in the ring
an be measured after either of these types of exposure conditions
y subtracting the amount remaining in the ring from the amount
f drug that was initially loaded into each ring, measured prior to
atch release.
Such an assessment must consider factors that can inﬂuence
1) the amount of dapivirine released into the surrounding envi-
onment, which would typically be the same factors that would
nﬂuence the amount of drug remaining in the ring; as well as (2)
he measurability of the amount of drug in the ring before and after
se.
Factors that can potentially inﬂuence the amount of dapivirine
eleased in the surrounding environment (or the amount of
apivirine remaining in the ring) include changes in the contin-
ous use of the product (removing the ring from the surrounding
nvironment), direct or indirect contact with the surrounding envi-
onment, and combinations of these. When tested in vitro, the
ontact with the surrounding environment (e.g., dissolution or
xtraction solvent) is continuous, and set-up to provide sink con-
itions, so that any release of dapivirine into the surrounding
nvironment is not impeded or impacted by the surrounding envi-
onment (i.e., the solubility of dapivirine in release media).
This is not the same for actual in-use conditions. In actual human
se conditions, the direct or indirect contact can be affected by
nsertion of the ring, so that the ring may  potentially end up with a
ess than maximum ring surface area contact with the vaginal walls.
he impact of this difference on the amount of drug released has
ot been assessed; however, variation in insertion is minimized by
roviding all users with standardized instructions for ring insertionorbital shaker at 60 rpm with 100 ml  media, replaced daily (200 ml  replacement on
Fridays as sampling did not occur on the weekends).
and by research staff checking the correct positioning of the ring.
Nevertheless, even if the same ring position in the vagina among
all users for every executed insertion is assumed, there are still
physical differences that may  impact the surface area contact. It
is not possible to identify or quantify all possible combinations of
differences between users, any combinations of which may impact
release of product during use. Furthermore, the ring may  be out
of the vagina, due to expulsion or intentional removal. This would
expose the ring to a different environment during these periods,
thus potentially affecting the total amount of dapivirine left in the
ring. Other factors that could inﬂuence the dapivirine released from
the ring include rinsing or washing the ring [11], and storing it for
an unspeciﬁed period of time in conditions of unknown sanitation.
Another potential factor for differences in the amount of dapivirine
released (inter-participant variability) during actual use is the dif-
ference in the vaginal environment itself. Basal body temperatures,
pH, bacterial microenvironments, etc., could affect the body’s abil-
ity to remove the dapivirine from the matrix (via either diffusion
or extraction mechanisms) and may  be inﬂuenced by a number of
factors such as fever, illness, infections (sexually transmitted and
non-speciﬁc infections), etc. Furthermore, women’s use of a range
of vaginal products to improve sexual intercourse, or for cleaning
before or after sex or menses, could affect the vaginal environment
[12].
Factors that can impact the measurability of the amount of
dapivirine in the ring before and after use include variability in
the initial drug load, variation due to the analytical method used to
determine the residual amounts and variation due to in-use condi-
tions. Although the target drug load for all rings is 25 mg  dapivirine
per ring, current speciﬁcations allow for drug load ranging from
9 al and Biomedical Analysis 125 (2016) 94–100
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Fig. 3. Comparison of in vivo and in vitro data for IPM 034.8 P. Spence et al. / Journal of Pharmaceutic
0.0% to 110.0% of the target label claim (25 mg). Therefore, an
cceptable ring may  contain anywhere from 22.5 mg  to 27.5 mg
apivirine. Although this degree of variability is allowed for release
f product, the actual variability, as one would expect for a late-
hase pharmaceutical drug product is signiﬁcantly less. Across 20
atches manufactured using the current process, the average assay
alue is 98.0% label claim (or 24.5 mg/ring), with a 1.87% RSD.
ariation may  be due to the analytical method used to determine
he residual amounts. The analytical method used to extract any
emaining dapivirine from rings was validated under “clean”/non-
linical use conditions; therefore, one must assume that in the
ost-use scenario there is as much as the standard accepted 2%
otential variation due to the combined method and equipment
ariables.
Variations due to in-use conditions might impact this 2%, since
fter rings are used and removed they are rinsed and patted dry,
hen placed into a pouch where they are stored until analysis.
hile stored at the research centers, these returned rings are stored
t ambient conditions. Occasionally, biological growth has been
bserved on some of the rings between the time of storage and the
ime of analysis, so it would theoretically be possible that exposure
o biological ﬂuids and potential biological growth on the ring may
mpact the ability to extract all remaining dapivirine from the ring
uring analysis. To address this potential, the study described in
ection 2 was completed and the results indicated that there was
o change in extracted amounts of drug versus expected amounts
f drug; however, there was  also no biological growth observed, so
he impact of visible microbial growth on post-use VR assay could
ot be determined.
.2. Potential use of residual drug analysis as a measure of
dherence in clinical trials
Results on dapivirine residual levels in post-use rings from three
linical trials of the dapivirine vaginal ring (Ring-004), conducted
y IPM, is presented in Table 2. On average, about 4 mg  of dapivirine
as released in vivo over the course of 28 days. In the Phase I/II trial,
PM 015, this corresponded to trough plasma levels (as determined
t the time of ring removal) typically <300 pg/ml, explained mech-
nistically by the transitioning of the drug from the vaginal mucosa
hrough barrier layers (i.e., epithelial) prior to entering the blood-
tream. Similar results were obtained for the Phase I clinical trials,
PM 028 and IPM 034 that were both conducted at a Phase I unit
n Belgium. Due to the better control of these trials (by virtue of
ore frequent clinical visits), it is expected that adherence would
e higher than might be seen in larger trials.
Results from the more recent Phase I trial, IPM 034, indicate that
 correlation exists between the amount of residual dapivirine and
he duration of ring use (Fig. 3); therefore, one would expect that
t would be theoretically possible to model and predict adherence
ased on observed ring residual amounts, given a signiﬁcant sample
ize.
The original design for the IPM 034 trial included a 7-day dura-
ion of ring use; however, the data from this group are excluded
rom consideration in this trend analysis due to analytical errors.
lthough the number of rings analyzed for the three trials described
n Table 2 ranged from 32 to 331, the residual dapivirine level data
ere observed to be within 10% of each other at the 28-day time
oint. This provides the basis for a prediction that the dapivirine
ing delivers, on average, about 4 mg  of dapivirine over a 28-day
se period. Moreover, as different batches of rings were used for
he three clinical trials, and manufactured at two  different sites,
hese results support that the technology used to manufacture the
ings provides reproducible, potentially predictable drug product,
onﬁrming the trends in similarity observed between lots in the
n vitro dissolution comparison presented in Fig. 1.In  vitro release conditions: 50:50 2-propanol:water, 37 ◦C, orbital shaker at 60 rpm
with 100 ml  media, replaced daily (200 ml  replacement on Fridays as sampling did
not occur on the weekends).
When plotted against the square root of time, both the in vivo
and in vitro data for the lot used in the clinical trial IPM 034 conform
to the Higuchi equation, with linear coefﬁcients of determination
calculated as 0.9958 and 0.9989, respectively (Fig. 3). This further
implies predictability by demonstrating that the in vivo release is
controlled primarily via a diffusion mechanism, similar to what was
observed in vitro. Despite the fact that all of the processes that
contribute to in vivo release mechanisms cannot be known, this
key comparison shows promise that residual drug level can be used
as one predictive tool for clinical trial adherence. Limitations of the
ability to predict directly from used ring data alone are realized in
that:
1. Inter-participant variability is seen in post-use ring values and
outliers are observed at both the high (low drug release) and
low (high drug release) end of the residual drug level spectrum
measured. In larger clinical studies (i.e., IPM 015 in this paper)
there is a larger incidence of outliers observed for residual drug
values that are greater than two standard deviations above the
average, presumably due to lower adherence to product use in
these participants.
2. For larger trials, analytical variability may  play an important
role, in regards to the number of rings analyzed and the labor
intensive nature of the sample preparation (e.g., in this case,
24-h extraction, followed by HPLC analysis). Based on the sheer
number of potential factors that can inﬂuence the amount of
dapivirine released in vivo (vide supra), it is not possible to
specify an exact amount of dapivirine to be released for each
participant. Since there is no “target” value for post-use ring
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Table  2
Residual dapivirine levels in post-use vaginal rings from clinical trials.
Clinical Trial Duration of ring use (d) Average drug released (mg)a SD Sample size (N)b
IPM 015 28 ± 4 4.4 1.6 331
IPM  028 28 4.4 1.5 67
IPM  034 14 2.5 0.3 8
28  4.0 0.6 8
56  7.1 0.8 8
84  9.1 1.2 8
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ta Lot average value at release (mg)—value obtained from post-use assay (mg). Av
b Number of rings analyzed.
assays, description of the overall variability can only be realisti-
cally achieved by conducting a statistical analysis on a large data
set of used rings and ﬂagging/investigating future values that fall
outside predeﬁned “outlier” criteria.
. Given the small amount of dapivirine that is released (about
4 mg  over a 28-day ring use period), the error inherent in the
analytical method itself, typically accepted as around 2% of the
label claim of 25 mg  (taking into account method and equipment
variability), corresponds to as much as 0.5 mg/ring.
It appears that pooled, blinded post-use residual dapivirine level
ata can provide an initial, general trend of some or no product
se in vaginal ring clinical trials. Despite the many variables that
ake it not possible to rely on these values alone, a more compre-
ensive indication of adherence from post-use residual dapivirine
evels can be triangulated with data from plasma or other phar-
acokinetic parameters (i.e., vaginal ﬂuid, or other parameters) to
rovide an objective measure of adherence during the conduct of
hase III trials.
. Conclusion
Validation (via simulated use) and stability studies have been
erformed on methodology used to determine dapivirine levels
n post-use vaginal rings, with the potential purpose of assessing
linical trial adherence. Samples rinsed in either whole blood or
imulated (proxy) vaginal ﬂuid were stored with or without rins-
ng for up to 6 months at room temperature (20–25 ◦C) and 24
onths at −20 ◦C, and no signiﬁcant differences in assay value were
bserved.
Data obtained by both in vitro and in vivo studies indicate that
apivirine is released according to a diffusion mechanism, by virtue
f conformance of both data sets to the Higuchi equation. This, cou-
led with the low variability associated with batch production over
wo sites and 20 batches of VRs [13], provides insight that post-
se ring analysis could be used as one tool in predicting adherent
se of VRs in clinical trials. Potential inter-participant variability
nd uncertainty associated with measuring the low amount of
apivirine actually released (about 4 mg  over a 28-day ring use
eriod) relative to the starting amount (about 25 mg)  are limita-
ions on the sole use of residual ring values as direct measurements
or adherence in vaginal ring clinical trials. A comprehensive model
o describe adherence, based on ring residual amounts and data
rom plasma and vaginal ﬂuids, will be proposed in future work,
nce the pivotal Phase III trials for the dapivirine vaginal ring are
ompleted.
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